Comments on: Extended-Release Stimulants for ADHD: FDA Drug Safety Communication – FDA Requires Expanded Labeling about Weight Loss Risk in Patients Younger than 6 Years

Comments on: Extended-Release Stimulants for ADHD: FDA Drug Safety Communication – FDA Requires Expanded Labeling about Weight Loss Risk in Patients Younger than 6 Years https://www.asebeylaw.com/extended-release-stimulants-for-adhd-fda-drug-safety-communication-fda-requires-expanded-labeling-about-weight-loss-risk-in-patients-younger-than-6-years/ Tue, 01 Jul 2025 04:00:00 +0000 hourly 1 https://wordpress.org/?v=6.8.3